OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis

This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called “Triplex”. Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12 (IL12) and allogeneic histocompatibility antigens) and was previously found able to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Nanni, Patrizia, De Giovanni, Carla, Burocchi, Alessia, Nicoletti, Giordano, Landuzzi, Lorena, Palladini, Arianna, Ianzano, Marianna Lucia, Arioli, Ivano, Colombo, Mario P., Lollini, Pier-Luigi
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136865/
https://ncbi.nlm.nih.gov/pubmed/30221061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1465164
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars